bluebird bio (BLUE)
(Delayed Data from NSDQ)
$1.03 USD
-0.02 (-1.90%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.04 +0.01 (0.97%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
bluebird bio, Inc. [BLUE]
Reports for Purchase
Showing records 501 - 520 ( 530 total )
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Initiating with a Buy rating and $50 target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Q2:14 EPS, Bluebird CEO Discusses Gene Therapy at LSMAC, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Acquires Pregenen for Gene Editing Technology; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Initial Beta-Thal Data De-risks LentiGlobin Program, Increasing PT to $51 (from $40)
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Initial Beta-Thal Data De-risks LentiGlobin Program, Increasing PT to $51 (from $40)
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
LentiGlobin Produces Early Transfusion Independence in First Two Beta-Thal Patients in Phase I/II Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
LentiGlobin Produces Early Transfusion Independence in First Two Beta-Thal Patients in Phase I/II Study, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 26
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Phase I/II Data in Beta-Thal Suggests Potential for Improved Clinical Outcomes with LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: bluebird bio, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Phase I/II Data in Beta-Thal Suggests Potential for Improved Clinical Outcomes with LentiGlobin, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D